Multiple Sclerosis Clinical Trial

Lipoic Acid for Progressive Multiple Sclerosis (MS)

Summary

The purpose of the study is to determine if lipoic acid can preserve mobility and protect the brain in progressive forms of multiple sclerosis.

View Full Description

Full Description

This two-year study will determine if daily oral intake of lipoic acid will prove superior to placebo in reducing injury to the brain and maintaining mobility in progressive MS. Mobility will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as fall counts. Neuroprotection will be measured by the extent of brain volume loss seen on MRI.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of progressive MS as defined by the study
Able to give informed consent and to adhere to study procedures.
Expanded Disability Status Scale (EDSS) 3.0 - 6.5: ambulatory for at least 20 meters without rest and use of bilateral aids (canes, crutches, walker) or better.

Exclusion Criteria:

A self-reported medical or neurological problem other than MS that is a cause of progressive or fluctuating gait dysfunction
Unable to undergo MRI
Unable to follow directions in English as standardized scales are not all validated in other languages.
Current major disease or disorder other than MS (e.g., cancer, renal disease, end-stage cardiopulmonary disease, post-traumatic stress disorder, etc.) that may interfere with study procedures. Note: Stable abnormal laboratory values of no more than Grade 1 determined to not be of clinical significance to the primary treating physician for that condition may be permitted per local site investigator discretion.
Pregnant or breast-feeding.
Insulin-dependent diabetes or diabetes not controlled on oral diabetes medications.
Scheduled (every 3 months or more frequently) IV or oral steroids in the year prior to enrolment.
IV or oral steroids in the 60 days prior to enrolment.
Use of LA in the prior 2 years exceeding the equivalent of 1200mg daily for 3 months.
Participation in the pilot LA in SPMS trial.

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

115

Study ID:

NCT03161028

Recruitment Status:

Active, not recruiting

Sponsor:

VA Office of Research and Development

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
University of Colorado
Aurora Colorado, 80045, United States
Washington DC VA Medical Center, Washington, DC
Washington District of Columbia, 20422, United States
VA Portland Health Care System, Portland, OR
Portland Oregon, 97207, United States
VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX
Dallas Texas, 75216, United States
University of Utah
Salt Lake City Utah, 84148, United States
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City Utah, 84148, United States
University of Vermont
Burlington Vermont, 05401, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle Washington, 98108, United States
Swedish Medical Center
Seattle Washington, 98122, United States
Ottawa Hospital Research Institute
Ottawa Ontario, K1Y 4, Canada

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Phase:

Phase 2

Estimated Enrollment:

115

Study ID:

NCT03161028

Recruitment Status:

Active, not recruiting

Sponsor:


VA Office of Research and Development

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.